Related Experiment Video
Updated: Jul 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia
Shin-ichiro Miura1, Keijiro Saku
1Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan. miuras@cis.fukuoka-u.ac.jp
Abstract:
Treatment of dyslipidemia is important for the primary and secondary prevention of cardiovascular events. Although statins induce the intensive lowering of low-density lipoprotein (LDL) cholesterol levels, two-thirds of cardiovascular events are not prevented. Ezetimibe has been shown to be a selective inhibitor of the Niemann-Pick C1-like 1 (NPC1L1) transporter of cholesterol across the intestinal wall. Ezetimibe-based therapy may hold the promise of more intensive lowering of LDL cholesterol. This review will address the beneficial effects of ezetimibe in patients with dyslipidemia.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Bioavailability Enhancement: Drug Permeability Enhancement